Nerve stimulation reduces impact of migraine
A pilot study has shown that non-invasive vagus nerve stimulation (nVNS) reduced the number of headache days per month for chronic migraine patients.
Read More
Author: Hugh Gosling
NICE approves Servier’s Lonsurf as third-line cancer therapy
The National Institute for Health and Care Excellence has recommended trifluridine/tipiracil as an option for treating metastatic colorectal cancer.
Read More
June issue of PharmaTimes – out now
Read the June issue of PharmaTimes now – digital and online.
Read MoreEngland’s pledge to recruit more GPs failing
Health secretary Jeremy Hunt’s plans to bring as many 400 doctors from India to the UK are an “admission of failure” of its recruitment policies, says the BMA.
Read MoreEU approval for Revolade for children with rare blood disorder
The European Commission has approved Novartis’ Revolade (eltrombopag) as a first-in-class therapy for children aged one and over with chronic idiopathic thrombocytopenic purpura (ITP) that have not responded to other treatments.
Read More- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
